Post Approval Study of the Eversense® Continuous Glucose Monitoring

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 273 participants.

Also called NCT03908125

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Not applicable
Enrolled
  • 273 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03908125
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03908125. Allocation not applicable; no masking; primary purpose diagnostic. Start 2019-03-19 (actual); primary completion 2024-02-01 (actual). Results posted on 2025-06-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Post Approval Study of the Eversense® Continuous Glucose Monitoring
Acronym
PAS
Condition
Diabetes Mellitus
Condition
Diabetes Mellitus, Type 1
Condition
Diabetes Mellitus, Type 2
Intervention (Device)
Eversense® CGM System
Lead sponsor
Senseonics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03908125
Content hash
44ae49ce7d92e8e078d4d04b3057069f737b71acdca283daf9611484dfb71ee0